Cannabis stocks surge after reports of Trump planning to ease federal restrictions
Advertisement
Read this article for free:
or
Already have an account? Log in here »
To continue reading, please subscribe:
Monthly Digital Subscription
$1 per week for 24 weeks*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*Billed as $4.00 plus GST every four weeks. After 24 weeks, price increases to the regular rate of $19.95 plus GST every four weeks. Offer available to new and qualified returning subscribers only. Cancel any time.
Monthly Digital Subscription
$4.99/week*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*Billed as $19.95 plus GST every four weeks. Cancel any time.
To continue reading, please subscribe:
Add Free Press access to your Brandon Sun subscription for only an additional
$1 for the first 4 weeks*
*Your next subscription payment will increase by $1.00 and you will be charged $16.99 plus GST for four weeks. After four weeks, your payment will increase to $23.99 plus GST every four weeks.
Read unlimited articles for free today:
or
Already have an account? Log in here »
TORONTO – Shares in Canada’s cannabis companies surged after reports U.S. President Donald Trump is planning to ease federal restrictions on the drug.
The Washington Post first reported that the president is expected to direct agencies to reclassify marijuana as a Schedule III drug.
The move would make it similar to some common prescription painkillers, the newspaper says.
A reclassification of the drug in the U.S. could offer an opportunity for Canadian cannabis companies to expand their businesses stateside.
Shares of Tilray Brands Inc. jumped 29 per cent or $3.35 to $14.94 in mid-morning trading Friday on the Toronto Stock Exchange, while Canopy Growth Corp. shares were up 32 per cent or 49 cents at $2.07. Aurora Cannabis Inc. shares were up 13 per cent and Organigram Global Inc. was up nearly 10 per cent.
While many states have passed laws legalizing cannabis for adult use in the U.S., federally it remains a Schedule I drug, the same category as heroin and LSD.
This report by The Canadian Press was first published Dec. 12, 2025.
Companies in this story: (TSX:TLRY, TSX:WEED, TSX:ACB, TSX:OGI)
Related Articles
Trump signs executive order that could reclassify marijuana as a less dangerous drug
Advertisement Advertise With Us